Interactions and monitoring
Linezolid: the medication list and CBC are part of the order
A linezolid order is more than an antibiotic-selection question. Serotonergic medicines, recent monoamine oxidase inhibitor use and blood-count monitoring can change the safety plan. Recover the actual medication history before treating an interaction alert as a checkbox to dismiss.
Sources checked October 8, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Distinguish the interaction branches
The cited label contraindicates linezolid with an MAOI or within two weeks of taking one. It separately warns about serotonin syndrome with serotonergic medicines, including antidepressants. Do not collapse the contraindication and the conditional urgent-treatment pathway into one vague rule that every antidepressant behaves identically.
Identify drug names, last doses and the reason linezolid is being used. A medicine discontinued yesterday may still matter. The full label describes circumstances in which urgent linezolid treatment may proceed with interruption and monitoring; that is a clinical decision, not permission to independently change psychiatric therapy.
Describe the syndrome rather than one symptom
The label describes serotonin-syndrome findings such as hyperthermia, rigidity, myoclonus, autonomic instability and mental-status change. New agitation with fever and abnormal movements needs urgent assessment, not reassurance that nausea is a common antibiotic effect.
Symptoms can have competing causes in an ill patient. Preserve the infection, timing and coexposures while escalating. Do not diagnose from a single symptom or tell a patient to wait for the next routine CBC when the presentation may be an acute syndrome.
Keep blood counts on the plan
Monitor complete blood counts weekly under the label, particularly with longer treatment and other risk factors. Myelosuppression may include anemia, leukopenia, pancytopenia and thrombocytopenia. A falling platelet count is not answered by an unchanged antibiotic dose alone.
Review the baseline, trend, treatment duration and other marrow-suppressing drugs with the team. The label advises considering discontinuation with developing or worsening myelosuppression. This lesson supports recognition and communication, not a universal platelet threshold or independent medication change.
Look beyond the first week
Peripheral and optic neuropathy are reported primarily with treatment beyond 28 days, and visual impairment warrants prompt ophthalmic assessment. The label also includes blood-pressure interactions and hypoglycemia in people using glucose-lowering therapy. A short interaction screen does not replace the full product safety review.
Record new visual symptoms and actual duration rather than assuming an oral antibiotic cannot have serious systemic effects. A plan that handles serotonin risk but omits CBC or symptom monitoring remains incomplete. Use the current label and clinical context for the full monitoring schedule.
A worked case
A patient prescribed linezolid also takes sertraline. The course is planned for several weeks, and there is no CBC plan. A colleague proposes telling the patient to stop sertraline immediately without contacting the treating team. What should be reviewed?
- Recover the indication, urgency, coexposures and last doses.
- Arrange clinician review of the serotonin-risk management plan rather than independently changing antidepressant therapy.
- Add the label-directed weekly CBC plan and symptom counseling.
Answer: The interaction and monitoring plan need coordinated review; neither dismissal nor an unsupervised psychiatric-drug change is adequate.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Is recent MAOI use irrelevant once the medicine is stopped?
No. The label contraindication includes use within the preceding two weeks.
2. Does serotonin-risk review replace blood-count monitoring?
No. Weekly CBC monitoring is a separate safety requirement.
3. New fever, agitation and myoclonus: wait for routine follow-up?
No. This symptom pattern needs urgent clinical assessment.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.